Harvard Bioscience and Etisense Announce Agreement for Supply and Distribution of DECRO Miniature Telemetry Jacket Platform for Pre-Clinical Research
Includes dedicated version for integration with Ponemah data management software from Data Sciences International (DSI)
Expands reach of unique, non-invasive wearable monitoring for pre-clinical research across North American and European markets
HOLLISTON, Mass. and LYON, France, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) and Etisense announced today that they have entered into an agreement to offer DECRO®, Etisense’s non-invasive telemetry jacket and associated physiological monitoring software, to a broad range of pre-clinical customers in the North American and European markets.
Harvard Bioscience’s Data Sciences International (DSI) pre-clinical business will serve as the exclusive distributor of Etisense’s line of DECRO telemetry jackets and software in North America, the United Kingdom, and Ireland. Etisense will also supply a dedicated version of its DECRO telemetry jackets to be marketed by DSI in North America and Europe. These telemetry jackets, which will expand DSI’s Jacketed External Telemetry (JET™) product line, will be specially adapted to integrate with DSI’s industry leading Ponemah™ monitoring and data management software.
DECRO is the first and only of its kind wearable respiratory, cardiac and physical activity monitoring solution for small mammalian models, answering unmet scientific and ethical needs in preclinical research. DECRO provides physiological endpoints required in safety-pharmacology, pre-IND toxicology studies of new drug candidates or in pathological research models, without using invasive or restraining techniques.
This innovative jacket enables low noise surface electrocardiogram (ECG) and high resolution Respiratory Inductive Plethysmography (RIP) with sensors integrated on the jacket and features an inertial motion unit to assess physical activity while the models move and live freely within study programs, supporting more true-to-life results.
For DSI’s JET product line, the DECRO jacket solution will be integrated with DSI’s Ponemah software platform, the industry’s premier data acquisition and analysis platform, which supports continuous data acquisition from many subjects and signal types. The Ponemah platform is designed to meet a broad range of pre-clinical research needs, including for contract research organization (CRO) and pharmaceutical customers. The Ponemah software is available in both good laboratory practice (GLP) compliant and non-GLP compliant versions.
Jim Green, Harvard Bioscience President and CEO, said, “Our relationship with Etisense marks another step in maintaining DSI’s leadership in pre-clinical research and aligns with Harvard Bioscience’s vision to meet the needs of our larger industrial customers such as CROs and pharma companies, as well as leading academic and government labs.”
Serge Savard, Harvard Bioscience Vice President of Product Management, said, “By integrating Etisense’s jacketed solution into our DSI portfolio, we further enhance our offering to toxicology research customers with simplified access to physiological endpoints. Etisense’s solution brings to customers a unique offering, either with Etisense’s DECRO as a standalone solution or integrated with DSI’s Ponemah, opening the possibilities for combined recordings with behavior studies, by using our recently announced new behavioral monitoring system.”
“We’re thrilled that this collaboration will bring non-invasive, small-mammal monitoring to customers across academic and industrial sectors, expanding our reach beyond Europe into North American markets.” said Timothé Flenet, PhD, CEO of Etisense. “And with Harvard Bioscience, there’s no better scientific, technical, and commercial portfolio to which we can contribute, to ensure more researchers can generate results with confidence and serenity.”
Under the new agreement, DSI will serve as the exclusive distributor of Etisense’s DECRO solution and DSI’s integrated JET - Ponemah product in the United States, Canada, the United Kingdom, and Ireland. In the European Union (outside of Ireland), Etisense will continue commercializing its DECRO product line, while DSI will commercialize the integrated solution. DECRO is available immediately and will be transferrable to and interoperable with DSI’s JET integration once available. The companies target first deliveries of the JET integration with Ponemah in the spring of 2024.
For product inquiries or orders:
For US, Canada, UK, and Ireland, please contact Sales@datasci.com.
About Harvard Bioscience
Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in North America, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.
For more information, please visit our website at https://www.harvardbioscience.com.
Etisense is an innovative biomedical engineering company based in Lyon, France, specialized in developing physiological monitoring technologies. The company was created with the idea that physiological monitoring should be simple and non-invasive to face the challenges of modern and ethical medical research. Incorporated in March 2018, as a spin-off of TIMC Lab (Université Grenoble Alpes, CNRS, Grenoble INP). Etisense’s expertise ranges from e-textiles to embedded electronics and signal processing analysis in order to deliver a truly holistic approach to high performance monitoring.
Etisense’s products are powered by a proprietary platform for synchronous biosignals acquisition and processing. This platform is a combination of textile engineering, high performance sensors and electronics, advanced signal processing algorithms and modern software experience with full web technologies.
The company has been supported by funding from SATT Linksium and Bpifrance throughout its development phases, by Angels Santé, Hara and a pool of Private Investors for seed funding roundtable and by EIT-Health and the AURA region to support commercial development. Etisense is also a member of the LyonBiopole competitive cluster ecosystem.
For more information visit: www.etisense.com.
This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions or statements that do not relate to historical matters. Forward-looking statements include, but are not limited to, information concerning expected future financial and operational performance including revenues, gross margins, earnings, cash and debt position, growth and the introduction of new products, and the strength of the Harvard Bioscience, Inc. (the Company”) market position and business model. Forward-looking statements are not guarantees of future performance and involve known and unknown uncertainties, risks, assumptions, and contingencies, many of which are outside the Company’s control. Risks and other factors that could cause the Company’s actual results to differ materially from those described its forward-looking statements include those described in the “Risk Factors” section of the Company’s most recently filed Annual Report on Form 10-K as well as in the Company’s other filings with the Securities and Exchange Commission. Forward-looking statements are based on the Company’s expectations and assumptions as of the date of this document. Except as required by law, the Company assumes no obligation to update forward-looking statements to reflect any change in expectations, even as new information becomes available.
Investors and Media
Harvard Bioscience, Inc.
For Etisense :
+33 6 79 46 94 38
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Northland Power Announces Financial Close of the 1.1 GW Baltic Power Offshore Wind Project in Poland Green Financing22.9.2023 22:33:21 CEST | Press release
TORONTO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Northland Power Inc. (“Northland” or the “Company”) (TSX: NPI), today announced that its Baltic Power offshore wind project (“Baltic Power” or the “project”) in Poland has met all conditions and reached financial close for its 20-year CAD-equivalent $5.2 billion non-recourse green financing. A consortium of 25 financial institutions is supporting the project, including the European Investment Bank (EIB), European Bank for Reconstruction and Development (EBRD), Euler Hermes, Export and Investment Fund of Denmark and Export Development Canada. Baltic Power will play an important role in helping the Polish government achieve its renewable energy target where installed capacity of offshore wind energy is expected to reach up to 11 GW by 2040. Once operational, Baltic Power is expected to provide clean energy to more than 1.5 million Polish households annually. ABOUT NORTHLAND POWER Northland Power is a global power producer dedicated to helping t
Brookfield Corporation Announces Results of Conversion of its Series 32 Preferred Shares22.9.2023 22:05:00 CEST | Press release
BROOKFIELD, NEWS, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Brookfield Corporation (NYSE: BN, TSX: BN) today announced that after having taken into account all election notices received by the deadline for the conversion of its Cumulative Class A Preference Shares, Series 32 (the “Series 32 Shares”) (TSX: BN.PF.A) into Cumulative Class A Preference Shares, Series 33 (the “Series 33 Shares”), there were 177,688 Series 32 Shares tendered for conversion, which is less than the one million shares required to give effect to conversion into Series 33 Shares. Accordingly, there will be no conversion of Series 32 Shares into Series 33 Shares and holders of Series 32 Shares will retain their Series 32 Shares. About Brookfield Corporation Brookfield Corporation (NYSE: BN, TSX: BN) is focused on compounding capital over the long term to earn attractive total returns for our shareholders. Today, our capital is deployed across three businesses – Asset Management, Insurance Solutions and our Operating Busi
Monument Achieves Commercial Production at Selinsing Gold Mine22.9.2023 20:11:07 CEST | Press release
VANCOUVER, British Columbia, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Monument Mining Limited (TSX-V: MMY and FSE: D7Q1) ("Monument" or the "Company") is pleased to announce that commercial production has been achieved at the Selinsing Gold Mine in Malaysia that has operated 30 days consecutive production of gold concentrate at 90% of designed capacity. Cathy Zhai, President and CEO of Monument Mining commented: "We are very pleased to announce this landmark event at the Selinsing gold mine. After 12 years gold bullion production that generated positive cash flow, now the Gold Sulphide Project will continue the legacy, based on such we move forward to the Murchison Gold Project and the corporate development as well. We thank the Monument Mining team and contractor partners for their dedication and hard work to achieve this commercial production milestone.” Figure 1: Selinsing Flotation Plant at Night is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4c385faa-226d-480e-b975-
Nokia Corporation: Repurchase of own shares on 22.09.202322.9.2023 20:00:00 CEST | Press release
Nokia Corporation Stock Exchange Release 22 September 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 22.09.2023 Espoo, Finland – On 22 September 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL328,9913.65CEUX40,7873.66AQEU12,5813.66TQEX5,6413.66Total388,0003.65 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 Januar
Fingerprint Cards AB (publ) offentliggör slutligt utfall i utnyttjandet av teckningsoptioner av serie 2022:1 och 2022:222.9.2023 19:00:00 CEST | Pressemelding
EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, DIREKT ELLER INDIREKT, INOM ELLER TILL USA (INKLUSIVE DESS TERRIRTORIER OCH BESITTNINGAR), AUSTRALIEN, JAPAN, KANADA, HONGKONG, NYA ZEELAND, SINGAPORE ELLER SYDAFRIKA ELLER NÅGON ANNAN JURISDIKTION DÄR DISTRIBUTION ELLER OFFENTLIGGÖRANDE SKULLE VARA OLAGLIGT ELLER KRÄVA REGISTERING ELLER ANDRA ÅTGÄRDER ENLIGT GÄLLANDE LAG. ANDRA RESTRIKTIONER ÄR TILLÄMPLIGA. VÄNLIGEN SE AVSNITTET "VIKTIG INFORMATION" I SLUTET AV DETTA PRESSMEDDELANDE. Fingerprint Cards AB:s (publ) (“Fingerprints” eller “Bolaget”) offentliggör utfallet från utnyttjandet av teckningsoptionerna av serie 2022:1 och 2022:2 (”Teckningsoptionerna”), vilka emitterades i samband med Bolagets företrädesemission av units under november/december 2022. Totalt utnyttjades 2 708 761 teckningsoptioner av serie 2022:2, motsvarande cirka 13,7 procent av utestående teckningsoptioner av serie 2022:2, till en teckningskurs om 1,30 SEK styck som berättigar till 1,03 B-aktier. Totalt t